Innovent Biologics’ Fulzerasib Receives NMPA Approval for Advanced NSCLC Treatment in China
Innovent Biologics Inc., a biopharmaceutical company based in China and listed on the Hong Kong...
Cancer
Akeso Biopharma’s Ivonescimab Earns Category 1 Recommendation in China’s 2024 Lung Cancer Clinical Guideline
Akeso Biopharma, a China-based pharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 9926),...
Henlius Biotech Secures Exclusive Rights to Commercialize Convalife’s Generic Neratinib in China and Abroad
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has entered...
J&J’s Rybrevant-Lazclude Combo Approved by FDA, Challenging AstraZeneca’s Tagrisso in NSCLC Treatment
Johnson & Johnson (J&J; NYSE: JNJ) has secured a new market approval in the United...
Shanghai Henlius Biotech Secures Exclusive Rights to Convalife Pharmaceuticals’ Generic Neratinib in China
SHANGHAI—Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has entered...
Johnson & Johnson’s Rybrevant-Lazclude Combo Approved by FDA for First-Line NSCLC Treatment
NEW YORK—Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has secured a significant regulatory milestone...
Genmab CEO Signals Potential for China Partnership as BioNTech Exits acasunlimab Collaboration
COPENHAGEN—In a strategic pivot following BioNTech (NASDAQ: BNTX)’s withdrawal from their co-development partnership on the...
Sichuan Kelun Pharmaceutical’s H1 2024 Report Highlights MSD Collaboration Milestones
CHENGDU—Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has released its financial report for the first...
Astellas Pharma’s Padcev Receives NMPA Approval for Urothelial Cancer Treatment
TOKYO—Astellas Pharma Inc. (TYO: 4503) has announced that its anti-HER3 antibody-drug conjugate (ADC), Padcev (enfortumab...
BioNTech’s BNT326/YL202 Clears FDA Hurdle, Advancing in Clinical Trials for Solid Tumor Treatment
FRANKFURT—BioNTech SE (NASDAQ: BNTX), a leading German biotechnology company, has announced that the US Food...
Genmab’s Tepkinly/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments
COPENHAGEN—Genmab A/S (NASDAQ: GMAB), a leading biotech company, has announced that the European Commission (EC)...
Sichuan Biokin Launches Phase III Trial for Bispecific ADC BL-B01D1 in Lung Cancer
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has commenced the first patient dosing in a...
Kelun Pharmaceutical’s Sacituzumab Tirumotecan Receives Priority Review for NSCLC Treatment
Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) has announced that its drug sacituzumab tirumotecan (SKB264/MK-2870)...
Astellas Pharma Secures UK Approval for First-in-Class Gastric Cancer Therapy Vyloy
Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has secured market approval in the...
Shandong Buchang Pharmaceuticals Partners with Lancet for BC001 Licensing in Eurasia
Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858), based in China, has announced plans to enter...
Qilu Pharmaceutical Gains Approval for Generic Dasatinib, Expanding CML Treatment Options in China
Qilu Pharmaceutical, based in China, has received marketing approval for its generic version of Bristol-Myers...
Ascentage Pharma Secures NMPA Approval for Phase III Trial of Lisaftoclax in MDS
Ascentage Pharma (HKG: 6855), based in China, has received approval from the National Medical Products...
Enhertu Gains Conditional Approval in China for Advanced HER2-Positive Gastric Cancer
Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate co-developed by AstraZeneca (NASDAQ: AZN, LON: AZN) and...
Wantai Biological’s HPV Vaccine Receives Priority Review from China’s CDE
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced that its nine-valent recombinant...
Junshi Biosciences Submits Twelfth Indication for PD-1 Inhibitor Loqtorzi in China
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a new indication filing...